Literature DB >> 17115148

Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.

M-A Estève1, B Devictor-Pierre, G Galy, N André, C Coze, B Lacarelle, J-L Bernard, S Monjanel-Mouterde.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17115148     DOI： 10.1007/s00228-006-0212-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  20 in total

1.  Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors:  W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.

Authors:  B C Widemann; M L Hetherington; R F Murphy; F M Balis; P C Adamson
Journal:  Cancer       Date:  1995-08-01       Impact factor: 6.860

3.  Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.

Authors:  B C Widemann; F M Balis; R F Murphy; J M Sorensen; M J Montello; M O'Brien; P C Adamson
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

4.  Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.

Authors:  T Pignon; B Lacarelle; F Duffaud; P Guillet; J Catalin; A Durand; S Monjanel; R Favre
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Safety of delayed leucovorin "rescue" following high-dose methotrexate in children.

Authors:  B M Camitta; J S Holcenberg
Journal:  Med Pediatr Oncol       Date:  1978

6.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.

Authors:  A G Huvos; G Rosen; R C Marcove
Journal:  Arch Pathol Lab Med       Date:  1977-01       Impact factor: 5.534

7.  Metabolic conversion of methotrexate in man.

Authors:  R C Donehower
Journal:  Recent Results Cancer Res       Date:  1980

8.  Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol.

Authors:  J P Cano; R Bruno; N Lena; R Favre; A Iliadis; A M Imbert
Journal:  Cancer Drug Deliv       Date:  1985

9.  Test dose for predicting high-dose methotrexate infusions.

Authors:  I G Kerr; J Jolivet; J M Collins; J C Drake; B A Chabner
Journal:  Clin Pharmacol Ther       Date:  1983-01       Impact factor: 6.875

10.  Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.

Authors:  S Buchen; D Ngampolo; R G Melton; C Hasan; A Zoubek; G Henze; U Bode; G Fleischhack
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640
View more
  6 in total

1.  Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.

Authors:  Brigitte C Widemann; Frank M Balis; AeRang Kim; Matthew Boron; Nalini Jayaprakash; Aiman Shalabi; Michelle O'Brien; Michelle Eby; Diane E Cole; Robert F Murphy; Elizabeth Fox; Percy Ivy; Peter C Adamson
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

2.  Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.

Authors:  Jeffrey R Scott; Yinmei Zhou; Cheng Cheng; Deborah A Ward; Hope D Swanson; Alejandro R Molinelli; Clinton F Stewart; Fariba Navid; Sima Jeha; Mary V Relling; Kristine R Crews
Journal:  Pediatr Blood Cancer       Date:  2015-01-28       Impact factor: 3.167

3.  Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.

Authors:  Anthony M Christensen; Jennifer L Pauley; Alejandro R Molinelli; John C Panetta; Deborah A Ward; Clinton F Stewart; James M Hoffman; Scott C Howard; Ching-Hon Pui; Alberto S Pappo; Mary V Relling; Kristine R Crews
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

4.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

5.  ERG induces taxane resistance in castration-resistant prostate cancer.

Authors:  Giuseppe Galletti; Alexandre Matov; Himisha Beltran; Jacqueline Fontugne; Juan Miguel Mosquera; Cynthia Cheung; Theresa Y MacDonald; Matthew Sung; Sandra O'Toole; James G Kench; Sung Suk Chae; Dragi Kimovski; Scott T Tagawa; David M Nanus; Mark A Rubin; Lisa G Horvath; Paraskevi Giannakakou; David S Rickman
Journal:  Nat Commun       Date:  2014-11-25       Impact factor: 14.919

6.  Glucarpidase to combat toxic levels of methotrexate in patients.

Authors:  Jacalyn M Green
Journal:  Ther Clin Risk Manag       Date:  2012-11-22       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.